Selective targeting of liposomes to macrophages using a ligand with high affinity for the macrophage scavenger

Patrick C N Rensen1, J C Emile Gras, Eva K Lindfors

  • 1Dept. of Endocrinology and Metabolic Diseases, Leiden University Medical Center, C4-R81, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands. P.C.N.Rensen@lumc.nl

Insights

Researchers developed SRA-specific liposomes using a novel ligand for targeted drug delivery to macrophages. This approach enhances drug efficacy for inflammatory diseases, atherosclerosis, and cancer.

Area of Science:

  • Biomedical Engineering
  • Drug Delivery Systems
  • Immunology

Background:

  • Macrophages are key players in inflammation, atherosclerosis, and cancer.
  • Targeting macrophages offers therapeutic potential for various diseases.
  • Scavenger Receptor A (SRA) is highly expressed on macrophages, making it an attractive target.

Purpose of the Study:

  • To develop SRA-specific liposomes for targeted drug delivery to macrophages.
  • To investigate the efficacy of a novel SRA-targeting ligand (LCO-dA2dG10) incorporated into liposomes.
  • To evaluate the impact of these targeted liposomes on drug delivery and therapeutic outcomes.

Main Methods:

  • Covalent attachment of a high-affinity SRA ligand (decadeoxyguanine) to lithocholic oleate (LCO-dA2dG10).
  • Incorporation of LCO-dA2dG10 into phosphatidylcholine liposomes to create SRA-specific drug carriers.
  • In vivo assessment of liposome serum clearance, SRA-dependency, and cellular association.
  • Evaluation of intracellular drug delivery and bioactivity of encapsulated dexamethasone-phosphate.

Main Results:

  • LCO-dA2dG10-liposomes exhibited rapid serum clearance (<2 min) dependent on SRA.
  • SRA-specific targeting was confirmed, as clearance was inhibited by SRA competitors.
  • Other negative surface charge modifications did not yield similar clearance profiles, highlighting LCO-dA2dG10's unique SRA-enhancement.
  • Targeted liposomes increased association with RAW264.7 cells and enhanced intracellular delivery of dexamethasone-phosphate.

Conclusions:

  • LCO-dA2dG10-liposomes demonstrate high specificity for SRA on macrophages.
  • This targeted delivery system enhances drug uptake and bioactivity within macrophages.
  • SRA-specific liposomes hold therapeutic promise for inflammatory disorders, atherosclerosis, and tumorigenesis.